LMP2A ITAM is essential for providing B cells with development and survival signals in vivo

被引:99
作者
Merchant, M [1 ]
Caldwell, RG [1 ]
Longnecker, R [1 ]
机构
[1] Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA
关键词
D O I
10.1128/JVI.74.19.9115-9124.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In Epstein-Barr virus-transformed B cells, known as lymphoblastoid cell lines (LCLs), LMP2A binds the tyrosine kinases Syk and Lyn, blocking B-cell receptor (BCR) signaling and viral lytic replication. SH2 domains in Syk mediate binding to a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) in LMP2A. Mutation of the LMP2A ITAM in LCLs eliminates Syk binding and allows for full BCR signaling, thereby delineating the significance of the LMP2A-Syk interaction. In transgenic mice, LMP2A causes a developmental alteration characterized by a block in surface immunoglobulin rearrangement resulting in BCR-negative B cells. Normally B cells lacking cognate BCR are rapidly apoptosed; however, LMP2A transgenic B cells develop and survive without a BCR When bred into the recombinase activating gene 1 null (RAG(-/-)) background, all LMP2A transgenic lines produce BCR-negative B cells that develop and survive in the periphery. These data indicate that LMP2A imparts developmental and survival signals to B cells in vivo. In this study, LMP2A ITAM mutant transgenic mice were generated to investigate whether the LMP2A ITAM is essential for the survival phenotype in vivo. LMP2A ITAM mutant B cells develop normally, although transgene expression is comparable to that in previously described nonmutated LMP2A transgenic B cells. Additionally, LMP2A ITAM mutant mice are unable to promote B-cell development or survival when bred into the RAG(-/-) background or when grown in methylcellulose containing interleukin-7. These data demonstrate that the LMP2A ITAM is required for LMP2A-mediated developmental and survival signals in vivo.
引用
收藏
页码:9115 / 9124
页数:10
相关论文
共 82 条
[31]   IGM RECEPTOR-MEDIATED TRANSACTIVATION OF THE IGH 3' ENHANCER COUPLES A NOVEL ELF-1-AP-1 PROTEIN COMPLEX TO THE DEVELOPMENTAL CONTROL OF ENHANCER FUNCTION [J].
GRANT, PA ;
THOMPSON, CB ;
PETTERSSON, S .
EMBO JOURNAL, 1995, 14 (18) :4501-4513
[32]   Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation [J].
Gulley, ML ;
Pulitzer, DR ;
Eagan, PA ;
Schneider, BG .
HUMAN PATHOLOGY, 1996, 27 (01) :20-27
[33]   EPSTEIN-BARR VIRUS-ASSOCIATED TYPICAL GASTRIC-CARCINOMA DETECTED BY IN-SITU HYBRIDIZATION AND POLYMERASE CHAIN-REACTION [J].
HARN, HJ ;
HO, LI ;
CHUNG, WH ;
LIN, JJ ;
LEE, HS ;
LEE, WH .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 (03) :253-254
[34]   Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK - Functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling [J].
Hashimoto, S ;
Iwamatsu, A ;
Ishiai, M ;
Okawa, K ;
Yamadori, T ;
Matsushita, M ;
Baba, Y ;
Kishimoto, T ;
Kurosaki, T ;
Tsukada, S .
BLOOD, 1999, 94 (07) :2357-2364
[35]  
HEMPEL WM, 1992, J IMMUNOL, V148, P3021
[36]   EBV GENE-EXPRESSION IN AN NPC-RELATED TUMOR [J].
HITT, MM ;
ALLDAY, MJ ;
HARA, T ;
KARRAN, L ;
JONES, MD ;
BUSSON, P ;
TURSZ, T ;
ERNBERG, I ;
GRIFFIN, BE .
EMBO JOURNAL, 1989, 8 (09) :2639-2651
[37]   The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases [J].
Ikeda, M ;
Ikeda, A ;
Longan, LC ;
Longnecker, R .
VIROLOGY, 2000, 268 (01) :178-191
[38]   BLNK required for coupling Syk to PLCγ2 and Rac1-JNK in B cells [J].
Ishiai, M ;
Kurosaki, M ;
Pappu, R ;
Okawa, K ;
Ronko, I ;
Fu, C ;
Shibata, M ;
Iwamatsu, A ;
Chan, AC ;
Kurosaki, T .
IMMUNITY, 1999, 10 (01) :117-125
[39]   Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase [J].
Jiang, A ;
Craxton, A ;
Kurosaki, T ;
Clark, EA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (07) :1297-1306
[40]  
Kieff Elliott, 1996, P1109